Document Detail

BlyS: a potential hallmark of multiple myeloma.
MedLine Citation:
PMID:  23276925     Owner:  NLM     Status:  MEDLINE    
Multiple myeloma (MM) is a plasma cell dyscrasia characterized by bone lesions and production of a paraprotein. B-lymphocyte stimulator (BLyS) and its receptor (BAFFR) were highly expressed on peripheral blood and bone marrow B cells in MM patients as compared to those with monoclonal gammopathy of unknown significance (MGUS) and healthy donors. Serum BLyS levels in MM patients were significantly higher than those in MGUS patients and healthy controls. BLyS expression was increased in bone marrow specimens from MM patients as ascertained by immunofluorescence. Furthermore, BLyS, together with IL-2 and IL-6, significantly promoted MM cell proliferation and BLyS receptor expression compared with that in the control group. Treatment with bortezomib, a therapeutic proteasome inhibitor induced apoptosis and repressed the proliferation of RPMI8226 and U266 cells through inhibition of NF-κB p65 and IκBα. These findings suggest that BLyS is involved in the immunopathogenesis of MM and may prove to be a hallmark of MM.
Ping Wang; Liu Qian; Xiangliang Yuan; Chaoying Hu; Liansheng Wang; Qiuyu Huang; Ping Miao; Qiwen Yu; Yanhui Ma; Jiying Zhang; Xuehua Chen; Bingya Liu; Lisong Shen; Dongqing Zhang
Related Documents :
3198615 - Terminally differentiated neonatal rat myocardial cells proliferate and maintain specif...
24444355 - Considerations in designing systems for large scale production of human cardiomyocytes ...
24854645 - Tubular regeneration: when can the kidney regenerate from injury and what turns failure...
24953655 - The transcription factor ahr prevents the differentiation of a stage 3 innate lymphoid ...
10891425 - Fates of human b-cell precursors.
16160745 - Downregulation of wnt signaling by increased expression of dickkopf-1 and -2 is a prere...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-01-01
Journal Detail:
Title:  Frontiers in bioscience (Landmark edition)     Volume:  18     ISSN:  1093-4715     ISO Abbreviation:  Front Biosci (Landmark Ed)     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-06-12     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  101612996     Medline TA:  Front Biosci (Landmark Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  324-31     Citation Subset:  IM    
Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, 227 South Chongqing Road, Shanghai 200025, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Apoptosis / drug effects
B-Cell Activating Factor / biosynthesis*
B-Cell Activation Factor Receptor / biosynthesis*
B-Lymphocytes / metabolism
Bone Marrow / metabolism
Boronic Acids / therapeutic use
Cell Line, Tumor
Middle Aged
Multiple Myeloma / drug therapy,  physiopathology*
Pyrazines / therapeutic use
Reg. No./Substance:
0/B-Cell Activating Factor; 0/B-Cell Activation Factor Receptor; 0/Boronic Acids; 0/Pyrazines; 0/TNFRSF13C protein, human; 0/bortezomib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A proposal: Source of single strand DNA that elicits the SOS response.
Next Document:  Novel immunoregulatory properties of EGCG on reducing inflammation in EAE.